Custom tailored financial subscription opportunities are available in individual research programs as well as on a broader scale in specific disease or therapeutic areas. We take a "blank-slate" approach toward structuring your direct investment in medical research allowing your creativity to best suit your business needs, risk tolerance, and financial capacity.

By way of example, a project commences with a pharmaceutical company fully financing specific drug and diagnostic target development in exchange for commercial rights to the discoveries yielded by the research effort. The initial and milestone investments required are tempered by negotiated royalty arrangements providing partial compensation to the research laboratories and academic institutions performing validation studies and any individuals and scientific organizations producing effective data analysis tools and techniques.

Often participation and funding subscriptions draw entirely from existing industry players who naturally assume both financial and business risk to achieve commensurate rewards. However, we set virtually no restrictions on funding subscribers. Private ownership in any aspect of the life science development cycle could prove to be a valuable asset. We will explore any financial structure sufficiently enabling these important research opportunities to move forward.

Market Perspective:

The global Life Science market generates revenues in excess of $638 billion annually - $550 billion in pharmaceuticals, $61 billion in biotechnology, and $27 billion in diagnostics as reported in December 2003 by Cap Gemini Ernst & Young (CGE&Y). The U.S. biotechnology market is particularly healthy boasting 1,457 firms; 326 of which are are publicly traded with a mid-April 2003 market capitalization of $206 billion according to the Biotechnology Industry Organization and CGE&Y.

Contact us to discuss your ideas today.